natgillin/translations-raw huggingface dataset:
If you could get pregnant while taking Dovato, you need to use a reliable method of barrier contraception (for example, a condom) with other methods of contraception including oral contraceptive (the pill) or other hormonal contraceptives (for example, implants or injections), to prevent pregnancy. 
Če bi lahko med jemanjem zdravila Dovato zanosili, morate za preprečitev nosečnosti poleg drugih načinov kontracepcije, vključno s peroralnimi kontraceptivi (kontracepcijske tablete) ali drugimi hormonskimi kontracepcijskimi sredstvi (na primer vsadki ali injekcije), uporabljati zanesljiv način pregradne kontracepcije (na primer kondom).
depression, anxiety, insomnia, abnormal dreams 
depresija, anksioznost, nespečnost, nenormalne sanje občasni:
Dolutegravir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages. 
Dolutegravir in lamivudin dokazano zavirata replikacijo laboratorijskih sevov in kliničnih izolatov HIV v številnih vrstah celic, vključno s transformiranimi linijami celic T, linijami, pridobljenimi iz monocitov/makrofagov ter v primarnih kulturah aktiviranih mononuklearnih celic iz periferne krvi (PMBCs - peripheral blood mononuclear cells) in monocitih/makrofagih.
People with advanced HIV infection or AIDS have weak immune systems, and are more likely to develop serious infections (opportunistic infections). 
Osebe z napredovalo okužbo s HIV ali AIDS imajo oslabljen imunski sistem in večjo verjetnost, da se pri njih razvije hujša okužba (oportunistične okužbe).
The adjusted difference was -2.6 (95% CI: -6.7; 1.5) for GEMINI-1 and0.7 (95% CI: -4.3; 2.9) for GEMINI-2 with a prespecified non-inferiority margin of 10%. 
Prilagojena razlika je bila -2,6 (95 % IZ: -6,7, 1,5) v GEMINI-1 in -0,7 (95 % IZ: -4,3, 2,9) v GEMINI-2 s predhodno določeno mejo neinferiornosti 10 %.
Ledipasvir/Sofosbuvir/ Lamvudine (with abacavir) 
ledipasvir/sofosbuvir/ lamvudin (z abacavirjem)
In vitro, lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known. 
In vitro je lamivudin zaviral OCT1 in OCT2; klinične posledice tega niso znane.
Exposure to dolutegravir was generally similar between healthy subjects and HIV-1-infected subjects. 
Izpostavljenost dolutegravirju je bila pri zdravih osebah in osebah, okuženih z virusom HIV-1, na splošno podobna.
Although the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/or long-term exposure to CART. 
Čeprav naj bi bila etiologija nastanka osteonekroze multifaktorska (vključujoč uporabo kortikosteroidov, difosfonatov, uživanje alkohola, hudo imunosupresijo in višji indeks telesne mase), so o primerih osteonekroze poročali predvsem pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo CART.
Dovato can be taken with or without food. 
Zdravilo Dovato se lahko vzame s hrano ali brez nje.
Dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OAT3. 
Dolutegravir lahko poviša plazemske koncentracije zdravil, katerih izločanje je odvisno od OAT3.
creatine phosphokinase (CPK) elevations alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations 
zvišane vrednosti kreatin-fosfokinaze (CPK) zvišane vrednosti alanin-aminotransferaze (ALT) in/ali aspartat-aminotransferaze (AST)
• a low red blood cell count (anaemia) or low white blood cell count (neutropenia). 
• zmanjšano število rdečih krvnih celic (anemija) ali zmanjšano število belih krvnih celic (nevtropenija).
These findings should be considered for any child exposed in utero to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown aetiology, particularly neurologic findings. 
Te ugotovitve je treba upoštevati pri vseh otrocih, ki so bili in utero izpostavljeni nukleozidnim in nukleotidnim analogom, in so se pri njih pojavile resne klinične ugotovitve neznane etiologije, še zlasti nevrološke.
Anti-infective products Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160 mg/800 mg once daily for 5 days/300 mg single dose) 
Protimikrobna zdravila trimetoprim/sulfametoksazol (kotrimoksazol)/lamivudin (160 mg/800 mg enkrat na dan 5 dni/enkratni odmerek 300 mg)
There are no clinical study data on the effects of Dovato in the paediatric population. 
Ni podatkov iz kliničnih študij o učinkih zdravila Dovato pri pediatrični populaciji.
→ See a doctor straight away. 
→ Nemudoma obiščite zdravnika.
You need to know about important signs and symptoms to look out for while you're taking Dovato. 
Pomembne znake in simptome morate poznati, da boste nanje pozorni med jemanjem zdravila Dovato.
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. 
Ker se lamivudin dializira, bi se za odpravljanje posledic zaužitja prevelikega odmerka lahko poslužili kontinuirane hemodialize, vendar pa to ni bilo raziskano.
Although lamivudine is a substrate of BCRP and P-gp in vitro, given its high absolute bioavailability, (see section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on lamivudine concentrations. 
Čeprav je lamivudin in vitro substrat BCRP in P-gp, glede na njegovo veliko absolutno biološko uporabnost (glejte poglavje 5.2) ni verjetno, da bi zavrtje teh efluksnih prenašalcev klinično pomembno vplivalo na koncentracijo lamivudina.
• cladribine, to treat leukaemia or multiple sclerosis 
• kladribin, za zdravljenje levkemije ali multiple skleroze
→Do not take a double dose to make up for a forgotten dose. 
→ Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Available toxicological data in animals has shown excretion of dolutegravir in milk. 
Razpoložljivi toksikološki podatki pri živalih so pokazali, da se dolutegravir izloča v mleko.
Dovato is a medicine that contains two active ingredients used to treat human immunodeficiency virus (HIV) infection: dolutegravir and lamivudine. 
Zdravilo Dovato vsebuje dve učinkovini, ki se uporabljata za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV): dolutegravir in lamivudin.
The mean systemic clearance of lamivudine is approximately 0.32 L/h/kg, predominantly by renal clearance (> 70%) via the organic cationic transport system. 
Srednja vrednost sistemskega očistka lamivudina je približno 0,32 l/h/kg, pri čemer glavni delež odpade na ledvični očistek (> 70%), ki poteka preko organskega kationskega transportnega sistema.
HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to lamivudine (IC50 fold changes < 3.0. 
Izolati HIV-1 (CRF01_AE n = 12, CRF02_AG n = 12 in podtip C ali CRF_AC n = 13) 37 nezdravljenih bolnikov v Afriki in Aziji so bili občutljivi na lamivudin (< 3,0-kratne spremembe IC50).
Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases. 
Zato morajo bolniki ostati pod skrbnim nadzorom zdravnika, ki ima izkušnje z zdravljenjem bolezni, povezanih s HIV.
Dolutegravir is present in the female and male genital tract. 
Dolutegravir je prisoten v ženskem in moškem genitalnem traktu.
Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone. 
Dolutegravir ni imel farmakodinamičnega učinka na luteinizirajoči hormon (LH), folikle stimulirajoči hormon (FSH) in progesteron.
This combination may increase the risk for lactic acidosis in patients with moderate renal impairment (stage 3a creatinine clearance 45- 59 mL/min) and a cautious approach is recommended. 
Ta kombinacija lahko pri bolnikih z zmerno okvaro ledvic (stadij 3a, očistek kreatinina 45-59 ml/min) poveča tveganje za laktacidozo, zato je priporočljiva previdnost.
Adolescents aged between 12 and 17 years and weighing at least 40 kg can take the adult dose of one tablet once a day. 
Mladostniki, stari med 12 in 17 let, ki tehtajo vsaj 40 kg, lahko jemljejo odmerek za odrasle, to je eno tableto enkrat na dan.
The higher lamivudine Cmax, is not considered clinically relevant. 
Povečanje Cmax lamivudina se ne smatra kot klinično pomembno.
Based on limited available data with the dolutegravir single entity or lamivudine single entity used in combination with other antiretroviral agents to treat adolescents (12 to 17 years), there were no additional types of adverse reactions beyond those observed in the adult population. 
Na podlagi omejenih razpoložljivih podatkov o uporabi dolutegravirja ali lamivudina kot samostojne entitete v kombinaciji z drugimi protiretrovirusnimi učinkovinami za zdravljenje mladostnikov (starih od 12 do 17 let) ni bilo nobenih dodatnih neželenih učinkov poleg tistih, ki so jih zabeležili pri odraslih.
• hyperactivity (excessive restlessness and movement) 
• hiperaktivnost (pretiran nemir in gibanje)
Oral contraceptives Ethinyl estradiol (EE) and Norgestromin (NGMN)/Dolutegravir 
Peroralni kontraceptivi etinilestradiol (EE) in norgestromin (NGMN)/dolutegravir
Effect of dolutegravir and lamivudine on the pharmacokinetics of other medicinal products 
Učinek dolutegravirja in lamivudina na farmakokinetiko drugih zdravil
Sulfamethoxazole: AUC ↔ 
sulfametoksazol: AUC 
What you need to know before you take Dovato 
Kaj morate vedeti, preden boste vzeli zdravilo Dovato
The efficacy of Dovato is supported by data from 2 identical 148-week, Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority controlled trials GEMINI-1 (204861) and GEMINI-2 (205543). 
Učinkovitost zdravila Dovato potrjujejo podatki 2 identičnih, 148-tedenskih randomiziranih, dvojno slepih, multicentričnih, kontroliranih preskušanj neinferiornosti faze III z vzporednimi skupinami, GEMINI-1 (204861) in GEMINI-2 (205543).
Lamivudine triphosphate shows significantly less affinity for host cell DNA polymerases. 
Lamivudin trifosfat ima občutno manjšo afiniteto do DNK polimeraz gostiteljske celice.
Preliminary data from a surveillance study has suggested an increased incidence of neural tube defects (0.9%) in mothers exposed to dolutegravir (a component of Dovato) at the time of conception compared with mothers exposed to non-dolutegravir containing regimens (0.1%). 
Preliminarni podatki iz opazovalne študije so pokazali večjo incidenco okvar nevralne cevi (0,9 %) pri materah, ki so bile ob spočetju izpostavljene dolutegravirju (sestavina zdravila Dovato), v primerjavi z materami, ki so bile izpostavljene režimom, ki niso vsebovali dolutegravirja (0,1 %).
Lamivudine, via its active metabolite 5'-triphosphates (TP) (an analogue for cytidine), inhibits reverse transcriptase of HIV-1 and HIV-2 through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. 
Lamivudin preko svojih aktivnih presnovkov 5'-trifosfatov (TP) (analog citidina) zavira reverzno transkriptazo virusov HIV-1 in HIV-2 preko vključitve monofosfatne oblike v verigo virusne DNK, kar ima za posledico prekinitev verige.
Some late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). 
Redko so poročali o nekaterih primerih nevroloških motenj, ki nastopijo kasneje (hipertonija, konvulzije, nenormalno obnašanje).
Carcinogenesis and mutagenesis 
Karcinogenost in mutagenost
Reduction of the metformin dose should be highly considered. 
Potreben je temeljit razmislek o zmanjšanju odmerka metformina.
Dolutegravir increased metformin concentrations. 
Dolutegravir je povečal koncentracijo metformina.
Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study). 
Dolutegravir se presnavlja predvsem preko glukoronidacije z UGT1A1 in v majhni meri s CYP3A (9,7 % skupnega odmerka, uporabljenega v študiji človeške masne bilance).
• sensation of weakness in the limbs. 
• občutek šibkosti v udih
Overall, the safety profile in patients co-infected with hepatitis B and/or C was similar to that observed in patients without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C co-infection for all treatment groups. 
Na splošno je bil varnostni profil pri bolnikih, ki so bili sočasno okuženi z virusom hepatitisa B in/ali C, podoben kot pri bolnikih brez sočasne okužbe z virusom hepatitisa B ali C, čeprav so bile stopnje nepravilnosti AST in ALT v podskupini s sočasno okužbo z virusom hepatitisa B in/ali C v vseh terapevtskih skupinah višje.
It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen. 
Ni znano, ali je vsa ta količina ali pa samo njen del neabsorbirana učinkovina ali pa je posledica biliarnega izločanja glukuronidnega konjugata, ki se v črevesni svetlini razgradi, tako da nastane osnovna spojina.
In vitro, dolutegravir was not a substrate of human OATP 1B1, OATP 1B3 or OCT 1. 
In vitro dolutegravir ni bil substrat za humani OATP 1B1, OATP 1B3 ali OCT 1.
The likelihood of metabolic drug interactions with lamivudine is low due to the small extent of hepatic metabolism (5-10%). 
Verjetnost presnovnih interakcij z drugimi zdravili je majhna zaradi majhnega obsega jetrne presnove (od 5 do 10 %).
• metformin, to treat diabetes 
• metformin, za zdravljenje sladkorne bolezni
• The other ingredients are microcrystalline cellulose, sodium starch glycolate, magnesium stearate, mannitol (E421), povidone (K29/32), sodium stearyl fumarate, hypromellose (E464), macrogol, titanium dioxide (E171). 
• Druge sestavine zdravila so mikrokristalna celuloza, natrijev karboksimetilškrob, magnezijev stearat, manitol (E421), povidon (K29/32), natrijev stearilfumarat, hipromeloza (E464), makrogol, titanov dioksid (E171).
Dovato film-coated tablets are oval, biconvex, white tablets debossed with 'SV 137' on one face. 
Dovato filmsko obložene tablete so ovalne, bikonveksne, bele tablete z vtisnjeno oznako 'SV 137' na eni strani.
Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2). 
Na podlagi in vivo in/ali in vitro podatkov ni pričakovati, da bi dolutegravir vplival na farmakokinetiko zdravil, ki so substrati glavnih encimov ali prenašalcev, kot so CYP3A4, CYP2C9 in P-gp (za več informacij glejte poglavje 5.2).
Delay in stopping treatment with Dovato or other suspect active substances after the onset of hypersensitivity may result in a life-threatening allergic reaction. 
Odlašanje z ukinitvijo zdravljenja z zdravilom Dovato ali drugimi zadevnimi učinkovinami ob pojavu preobčutljivosti ima lahko za posledico življenjsko nevarno alergijsko reakcijo.
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment. 
Delež nevezanega dolutegravirja v plazmi se pri nizkih vrednostih serumskega albumina (< 35 g/l) poveča, kar je opazno pri osebah z zmerno okvaro jeter.
A study of the pharmacokinetics of dolutegravir was performed in subjects with severe renal impairment (CLcr <30 mL/min). 
Študijo farmakokinetike dolutegravirja so izvedli pri preiskovancih s hudo okvaro ledvic (Clcr < 30 ml/min).
Marketing Authorisation Holder ViiV Healthcare BV Huis ter Heideweg 62 
ViiV Healthcare BV Huis ter Heideweg 62
Some clinical findings also support a possible interaction between lamivudine and cladribine. 
Nekatere klinične ugotovitve potrjujejo tudi možno medsebojno delovanje med lamivudinom in kladribinom.
If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next dose is not due within 4 hours. 
Če bolnik izpusti odmerek zdravila Dovato, ga mora vzeti čim prej, pod pogojem, da do naslednjega odmerka ni manj kot 4 ure.
The film-coated tablets are provided in bottles closed with child-resistant closures. 
Filmsko obložene tablete so na voljo v vsebnikih, zaprtih z zaporko, varno za otroke.
Thirty-two percent of the total oral dose is excreted in the urine, represented by ether glucuronide of dolutegravir (18.9% of total dose), N-dealkylation metabolite (3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (3.0% of total dose). 
Dvaintrideset odstotkov celotnega peroralnega odmerka se izloči z urinom, bodisi v obliki dolutegravirjevega glukuronida (18,9 % celotnega odmerka), metabolita N-dealkilacije (3,6 % celotnega odmerka) in metabolita, ki nastane z oksidacijo na benzilnem ogljiku (3,0 % celotnega odmerka).
If Dovato is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis. 
Če pri bolnikih, ki so sočasno okuženi z virusom hepatitisa B, zdravilo Dovato ukinemo, je potrebno periodično spremljati tako teste jetrne funkcije kot označevalce replikacije virusa HBV, saj lahko ukinitev lamivudina vodi v akutno poslabšanje hepatitisa.
• breakdown of muscle tissue. 
• razpad mišičnega tkiva
You may need extra checkups, including blood tests, while you're taking your medicine. 
Morda boste med jemanjem tega zdravila potrebovali dodatne preglede, vključno s preiskavami krvi.
For Dovato, the median time to maximal plasma concentration (tmax) is 2.5 hours for dolutegravir and 1.0 hour for lamivudine, when dosed under fasted conditions. 
Za zdravilo Dovato je mediani čas za dosego maksimalne koncentracije v plazmi (tmax) 2,5 ure za dolutegravir in 1,0 uro za lamivudin, pri uporabi na tešče.
There are no data available on the safety of lamivudine when administered to babies less than three months old. 
O varnosti lamivudina, uporabljenega pri dojenčkih, mlajših od treh mesecev, ni podatkov.
Similar IC50s were seen for clinical isolates without any major difference between subtypes; in a panel of 24 HIV-1 isolates of clades A, B, C, D, E, F and G and group O the mean IC50 value was 0.2 nM (range 0.02-2.14). 
Podobne vrednosti IC50 so bile zabeležene pri kliničnih izolatih brez večjih razlik med podtipi; povprečna vrednost IC50 v panelu 24 izolatov HIV-1 podskupin A, B, C, D, E, F in G ter skupine O je bila 0,2 nM (razpon 0,02 - 2,14).
The IC50 values of lamivudine against HIV-1 subtypes (A-G) ranged from 0.001 to 0.170 µM, against Group O from 0.030 to 0.160 µM and against HIV-2 isolates from 0.002 to 0.120 µM in peripheral blood mononuclear cells. 
Vrednosti IC50 za lamivudin proti podtipom HIV-1 (A-G) so segale od 0,001 do 0,170 M, proti skupini O od 0,030 do 0,160 M in proti izolatom HIV-2 od 0,002 do 0,120 M v mononuklearnih celicah periferne krvi.
In vivo, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 or MATE-1 (e.g. metformin) (see Table 1 and section 4.3). 
In vivo lahko dolutegravir zviša plazemske koncentracije zdravil, katerih izločanje je odvisno od OCT2 ali MATE-1 (npr. metformin) (glejte Preglednico 1 in poglavje 4.3).
• suicidal attempt (particularly in patients who have had depression or mental health problems before) 
• poskus samomora (zlasti pri bolnikih, ki so že imeli depresijo ali težave z duševnim zdravjem)
If the next dose is due within 4 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Če je čas do naslednjega odmerka manj kot 4 ure, bolnik ne sme vzeti pozabljenega odmerka, ampak preprosto nadaljuje z jemanjem po ustaljenem urniku.
The stated reductions in dolutegravir exposure were observed with the intake of dolutegravir and these supplements during fasted conditions. 
Navedena zmanjšanja v izpostavljenosti dolutegravirju so opazili pri jemanju dolutegravirja in teh dodatkov na tešče.
Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with “SV 137” on one face. 
Ovalna, bikonveksna, bela, filmsko obložena tableta, velikosti približno 18,5 x 9,5 mm, ki ima na eni strani vtisnjeno oznako “SV 137”.
Other medicines and Dovato Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
More than 1000 outcomes from second and third trimester exposure to dolutegravir in pregnant women indicate no evidence of increased risk of malformative and foeto/neonatal negative effects. 
Več kot 1.000 primerov izpostavljenosti nosečnic dolutegravirju v drugem in tretjem trimesečju ne nakazuje dokazov o povečanem tveganju za deformacije in negativne učinke na plod/novorojenčka.
Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1). 
Zdravilo Dovato je indicirano za zdravljenje odraslih in mladostnikov, starejših od 12 let, ki tehtajo vsaj 40 kg, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), pri katerih ni znane ali domnevne odpornosti na skupino zaviralcev integraze ali na lamivudin (glejte poglavje 5.1).
In lactating rats that received a single oral dose of 50 mg/kg at 10 days postpartum, dolutegravir was detected in milk at concentrations typically higher than blood. 
Pri podganah v laktaciji, ki so prejele enkratni peroralni odmerek 50 mg/kg 10. dan po kotitvi, so bile ugotovljene koncentracije dolutegravirja v mleku značilno višje od tistih v krvi.
In these cases the physician should refer to the individual product information for dolutegravir. 
V takšnih primerih mora zdravnik upoštevati podatke o zdravilu, ki vsebuje dolutegravir.
Interaction studies have only been performed in adults. 
Pediatrična populacija Študije medsebojnega delovanja so izvedli le pri odraslih.
The efficacy of Dovato, or the dual combination of dolutegravir plus lamivudine (as single entities) has not been studied in children or adolescents. 
Učinkovitosti zdravila Dovato oziroma dvojne kombinacije dolutegravirja in lamivudina (kot v ločenih pripravkih) pri otrocih in mladostnikih niso raziskali.
• suicidal thoughts (particularly in patients who have had depression or mental health problems before). 
• samomorilne misli (zlasti pri bolnikih, ki so že imeli depresijo ali težave z duševnim zdravjem).
Uncommon side effects that may show up in blood tests are: 
Občasni neželeni učinki, ki se lahko pokažejo v preiskavah krvi, so:
Trimethoprim: AUC ↔ 
trimetoprim: AUC 
Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP). 
Dolutegravir je tudi substrat za UGT1A3, UGT1A9, CYP3A4, P-glikoprotein (P-gp) in protein odpornosti pri raku dojke (BCRP).
As hepatic elimination plays a minor role in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical significance. 
Ker ima odstranjevanje preko jeter pri očistku lamivudina manjšo vlogo, ni verjetno, da bi bila medsebojna delovanja zdravil zaradi zavrtja OCT1 klinično pomembna.
The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%). 
Incidenca okvar nevralne cevi pri splošni populaciji je od 0,5 primera do 1 primer na 1.000 živorojenih otrok (0,05 % - 0,1 %).
Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (< 1% of the dose). 
Dolutegravir je prevladujoča spojina, ki kroži v plazmi, izločanje nespremenjene zdravilne učinkovine skozi ledvice je majhno (< 1 % odmerka).